17-N-Allylamino-17-demethoxygeldanamycin

WikiDoc Resources for 17-N-Allylamino-17-demethoxygeldanamycin
Articles
Most recent articles on 17-N-Allylamino-17-demethoxygeldanamycin Most cited articles on 17-N-Allylamino-17-demethoxygeldanamycin Review articles on 17-N-Allylamino-17-demethoxygeldanamycin Articles on 17-N-Allylamino-17-demethoxygeldanamycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on 17-N-Allylamino-17-demethoxygeldanamycin Images of 17-N-Allylamino-17-demethoxygeldanamycin Photos of 17-N-Allylamino-17-demethoxygeldanamycin Podcasts & MP3s on 17-N-Allylamino-17-demethoxygeldanamycin Videos on 17-N-Allylamino-17-demethoxygeldanamycin
Evidence Based Medicine
Cochrane Collaboration on 17-N-Allylamino-17-demethoxygeldanamycin Bandolier on 17-N-Allylamino-17-demethoxygeldanamycin TRIP on 17-N-Allylamino-17-demethoxygeldanamycin
Clinical Trials
Ongoing Trials on 17-N-Allylamino-17-demethoxygeldanamycin at Clinical Trials.gov Trial results on 17-N-Allylamino-17-demethoxygeldanamycin Clinical Trials on 17-N-Allylamino-17-demethoxygeldanamycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on 17-N-Allylamino-17-demethoxygeldanamycin NICE Guidance on 17-N-Allylamino-17-demethoxygeldanamycin NHS PRODIGY Guidance FDA on 17-N-Allylamino-17-demethoxygeldanamycin CDC on 17-N-Allylamino-17-demethoxygeldanamycin
Books
Books on 17-N-Allylamino-17-demethoxygeldanamycin
News
17-N-Allylamino-17-demethoxygeldanamycin in the news Be alerted to news on 17-N-Allylamino-17-demethoxygeldanamycin News trends on 17-N-Allylamino-17-demethoxygeldanamycin
Commentary
Blogs on 17-N-Allylamino-17-demethoxygeldanamycin
Definitions
Definitions of 17-N-Allylamino-17-demethoxygeldanamycin
Patient Resources / Community
Patient resources on 17-N-Allylamino-17-demethoxygeldanamycin Discussion groups on 17-N-Allylamino-17-demethoxygeldanamycin Patient Handouts on 17-N-Allylamino-17-demethoxygeldanamycin Directions to Hospitals Treating 17-N-Allylamino-17-demethoxygeldanamycin Risk calculators and risk factors for 17-N-Allylamino-17-demethoxygeldanamycin
Healthcare Provider Resources
Symptoms of 17-N-Allylamino-17-demethoxygeldanamycin Causes & Risk Factors for 17-N-Allylamino-17-demethoxygeldanamycin Diagnostic studies for 17-N-Allylamino-17-demethoxygeldanamycin Treatment of 17-N-Allylamino-17-demethoxygeldanamycin
Continuing Medical Education (CME)
CME Programs on 17-N-Allylamino-17-demethoxygeldanamycin
International
17-N-Allylamino-17-demethoxygeldanamycin en Espanol 17-N-Allylamino-17-demethoxygeldanamycin en Francais
Business
17-N-Allylamino-17-demethoxygeldanamycin in the Marketplace Patents on 17-N-Allylamino-17-demethoxygeldanamycin
Experimental / Informatics
List of terms related to 17-N-Allylamino-17-demethoxygeldanamycin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

17-N-Allylamino-17-demethoxygeldanamycin is a substance that is being studied in the treatment of cancer, specific young patients with certain types of leukemia or solid tumors, especially kidney tumors. As of June 2005, 17-N-allylamino-17-demethoxygeldanamycin is undergoing Phase 1 and Phase 2 clinical trials. It belongs to the family of drugs called antitumor antibiotics.

External links

• Phase 1 trial
• Another Phase 1 trial
• National Cancer Institutie Bulletin on Phase 2 trials against Von Hippel-Lindau disease
• Safety sheet for 17AAG